导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.63% | 3282/4773 |
| 近一周 | -0.17% | 164/5462 |
| 近一月 | 4.20% | 99/5421 |
| 近一季 | 4.28% | 318/5209 |
| 近半年 | 2.78% | 940/4920 |
| 近一年 | -0.38% | 2719/4366 |
| 近两年 | 38.10% | 1973/2954 |
| 近三年 | 40.33% | 714/2253 |
| 成立以来 | 186.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.53% 4382/4961 |
-5.29% 3558/5312 |
- - |
- - |
| 2025 | 14.37% 2609/4813 |
0.13% 1972/3635 |
10.55% 245/4076 |
-4.84% 4026/4524 |
8.58% 236/4813 |
| 2024 | 40.14% 17/3463 |
5.28% 377/2808 |
4.45% 212/3014 |
23.46% 398/3129 |
3.23% 851/3463 |
| 2023 | -1.58% 522/2656 |
-1.17% 1855/2280 |
2.89% 119/2385 |
5.18% 97/2515 |
-7.97% 2226/2655 |
| 2022 | -7.15% 136/2207 |
-3.13% 157/1919 |
-0.52% 1631/2016 |
-9.41% 278/2113 |
6.36% 367/2208 |
| 2021 | -0.84% 763/1822 |
1.98% 236/1255 |
0.38% 1102/1330 |
-3.37% 636/1466 |
0.25% 1151/1822 |
| 2020 | 3.82% 911/1250 |
-14.90% 974/1028 |
4.26% 912/1067 |
9.02% 682/1164 |
7.33% 718/1184 |
| 2019 | 33.28% 435/1092 |
23.78% 540/754 |
2.96% 65/804 |
-1.57% 668/850 |
6.24% 638/918 |
| 2018 | -16.16% 105/834 |
- - |
- - |
- - |
-10.32% 188/691 |
| 2017 | 25.81% 110/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.93% 186/605 |
- - |
- - |
- - |
- - |
| 2015 | -7.73% 283/575 |
- - |
- - |
- - |
- - |
| 2014 | 83.06% 6/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 上证金融地产发起式ETF VS. 长安沪深300非周期A(740101) |